What is Chardan Capital’s Forecast for MNPR FY2025 Earnings?

Monopar Therapeutics Inc. (NASDAQ:MNPR) – Equities research analysts at Chardan Capital upped their FY2025 earnings per share estimates for Monopar Therapeutics in a research note issued on Wednesday, August 13th. Chardan Capital analyst K. Nakae now anticipates that the company will post earnings per share of ($1.93) for the year, up from their previous forecast of ($2.02). Chardan Capital has a “Buy” rating and a $60.00 price objective on the stock. The consensus estimate for Monopar Therapeutics’ current full-year earnings is ($1.65) per share. Chardan Capital also issued estimates for Monopar Therapeutics’ FY2026 earnings at ($3.01) EPS.

Monopar Therapeutics (NASDAQ:MNPR) last posted its earnings results on Tuesday, August 12th. The company reported ($0.35) earnings per share for the quarter, beating the consensus estimate of ($0.47) by $0.12.

Several other research firms have also weighed in on MNPR. Wall Street Zen upgraded Monopar Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday, May 22nd. Cantor Fitzgerald started coverage on Monopar Therapeutics in a research note on Monday, July 7th. They issued an “overweight” rating and a $74.00 price objective on the stock. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $60.00.

Monopar Therapeutics Price Performance

NASDAQ MNPR opened at $35.71 on Monday. Monopar Therapeutics has a fifty-two week low of $2.15 and a fifty-two week high of $54.30. The stock’s 50-day moving average is $38.02 and its two-hundred day moving average is $37.79. The firm has a market cap of $220.33 million, a P/E ratio of -10.72 and a beta of 1.05.

Hedge Funds Weigh In On Monopar Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. JPMorgan Chase & Co. acquired a new stake in Monopar Therapeutics during the fourth quarter valued at approximately $45,000. RA Capital Management L.P. acquired a new stake in Monopar Therapeutics during the fourth quarter valued at approximately $11,247,000. Geode Capital Management LLC boosted its holdings in Monopar Therapeutics by 174.4% during the fourth quarter. Geode Capital Management LLC now owns 38,596 shares of the company’s stock valued at $849,000 after purchasing an additional 24,530 shares in the last quarter. Janus Henderson Group PLC acquired a new stake in Monopar Therapeutics during the fourth quarter valued at approximately $23,435,000. Finally, Gerber LLC acquired a new stake in Monopar Therapeutics during the first quarter valued at approximately $204,000. 1.83% of the stock is currently owned by institutional investors.

Insider Transactions at Monopar Therapeutics

In other news, Director Christopher M. Starr sold 16,800 shares of Monopar Therapeutics stock in a transaction dated Monday, July 14th. The stock was sold at an average price of $40.00, for a total value of $672,000.00. Following the transaction, the director directly owned 5,173 shares in the company, valued at approximately $206,920. The trade was a 76.46% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Kim R. Tsuchimoto sold 8,904 shares of the business’s stock in a transaction dated Monday, July 14th. The shares were sold at an average price of $40.00, for a total value of $356,160.00. Following the transaction, the director owned 11,486 shares in the company, valued at $459,440. This represents a 43.67% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 42,504 shares of company stock worth $1,700,160. Company insiders own 20.50% of the company’s stock.

About Monopar Therapeutics

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.